<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/54458">
      <dc:title>Effect of monotherapy with darunavir/ cobicistat on viral load and semen quality of HIV-1 patients</dc:title>
      <dc:creator>López Ruz, Miguel Ángel</dc:creator>
      <dc:creator>López Zúñiga, Miguel Ángel</dc:creator>
      <dc:creator>Gonzalvo, María Carmen</dc:creator>
      <dc:creator>Samperdo, Antonio</dc:creator>
      <dc:creator>Pasquau Liaño, Juan</dc:creator>
      <dc:creator>Hidalgo, Carmen</dc:creator>
      <dc:creator>Rosario, Javier</dc:creator>
      <dc:creator>Castilla, Jose Antonio</dc:creator>
      <dc:description>Many patients previously using darunavir/ritonavir (DRV/r) (800/100mg) have switched to&#xd;
darunavir/cobicistat (DRV/C) (800/150 mg) either as part of triple therapy (ART) or as monotherapy&#xd;
with DRV (mDRV). The latter approach continues to be used in some countries for&#xd;
patients receiving long-term treatment. However, to date, the behaviour of DRV/C in the&#xd;
seminal compartment has not been analysed. This study explores how the combination&#xd;
behaves in monotherapy, with respect to the control of viral load and seminal quality. To this&#xd;
end, we studied 20 patients who were treated with mDRV/C after previous treatment with&#xd;
mDRV/r for at least 24 weeks. A viral load control in seminal plasma similar to that published&#xd;
in the literature was observed after 24 weeks of treatment with mDRV/C (viral load positivity&#xd;
in 20% of patients). Similarly, semen quality was confirmed (70% normozoospermic) in&#xd;
patients treated with this formulation, as has previously been reported for ART and mDRV/r.&#xd;
The DRV levels measured in seminal plasma were above EC50, regardless of whether the&#xd;
seminal viral load was positive or negative. We conclude that this mDRV/C co-formulation&#xd;
behaves like mDRV/r in seminal plasma in terms of viral load control and semen quality.</dc:description>
      <dc:date>2019-01-11T07:36:40Z</dc:date>
      <dc:date>2019-01-11T07:36:40Z</dc:date>
      <dc:date>2018-04-24</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:identifier>López-Ruz MA, López-Zúñiga MA, Gonzalvo MC, Sampedro A, Pasquau J, Hidalgo C, et al. (2018) Effect of monotherapy with darunavir/ cobicistat on viral load and semen quality of HIV-1 patients. PLoS ONE 13(4). 	[http://digibug.ugr.es/handle/10481/54458]</dc:identifier>
      <dc:identifier>1932-6203</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/54458</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by-nc/3.0/es/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:rights>Atribución-NoComercial 3.0 España</dc:rights>
      <dc:publisher>Alan Winston, Imperial College London, UNITED KINGDOM</dc:publisher>
   </ow:Publication>
</rdf:RDF>